Zhejiang Dayang Biotech Group Co Net Asset Quality Index
Zhejiang Dayang Biotech Group Co net asset quality index. Zhejiang Dayang Biotech Group Co (003017) has a Net Asset Quality Index of 62.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.88 Billion minus total liabilities of CN¥706.73 Million yields net assets of CN¥1.17 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 003017 total equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Zhejiang Dayang Biotech Group Co (2013–2025)
Net asset quality index of Zhejiang Dayang Biotech Group Co from 2013 to 2025. This chart shows how Zhejiang Dayang Biotech Group Co's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 62.4%, representing net assets of CN¥1.17 Billion against total assets of CN¥1.88 Billion CNY. Check 003017 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Zhejiang Dayang Biotech Group Co Net Asset Quality Index by Year (2013–2025)
Zhejiang Dayang Biotech Group Co net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for Zhejiang Dayang Biotech Group Co from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 003017 stock market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 62.5% | CN¥1.14 Billion | CN¥1.82 Billion | CN¥681.72 Million | ▼ -1.2 pp |
| 2024 | 63.7% | CN¥1.05 Billion | CN¥1.65 Billion | CN¥600.40 Million | ▼ -1.5 pp |
| 2023 | 65.2% | CN¥1.01 Billion | CN¥1.55 Billion | CN¥538.47 Million | ▼ -0.1 pp |
| 2022 | 65.3% | CN¥985.05 Million | CN¥1.51 Billion | CN¥522.92 Million | ▼ -6.8 pp |
| 2021 | 72.1% | CN¥990.71 Million | CN¥1.37 Billion | CN¥383.64 Million | ▼ -5.9 pp |
| 2020 | 78.0% | CN¥958.13 Million | CN¥1.23 Billion | CN¥270.67 Million | ▲ +0.8 pp |
| 2019 | 77.2% | CN¥498.09 Million | CN¥645.60 Million | CN¥147.51 Million | ▲ +3.9 pp |
| 2018 | 73.2% | CN¥440.62 Million | CN¥601.61 Million | CN¥160.99 Million | ▲ +7.4 pp |
| 2017 | 65.8% | CN¥337.71 Million | CN¥513.08 Million | CN¥175.37 Million | ▲ +16.7 pp |
| 2016 | 49.1% | CN¥229.35 Million | CN¥466.72 Million | CN¥237.37 Million | ▲ +3.4 pp |
| 2015 | 45.7% | CN¥209.76 Million | CN¥458.88 Million | CN¥249.12 Million | ▲ +3.2 pp |
| 2014 | 42.5% | CN¥196.87 Million | CN¥463.30 Million | CN¥266.43 Million | ▲ +0.0 pp |
| 2013 | 42.5% | CN¥187.42 Million | CN¥441.35 Million | CN¥253.93 Million | — |